Malignant high-grade gliomas are the most common and aggressive type of primary brain tumor, and the prognosis is generally extremely poor. In this retrospective study, we analyzed the outcome of systemic treatment in recurrent high-grade glioma patients and the impact of prognostic factors on survivals.
Methods
Data from 114 patients with recurrent high-grade glioma who received systemic treatment and followed in our clinic between 2012 and 2018 were retrospectively analyzed. Eastern Cooperative Oncology Group (ECOG) performance status, age, gender, histology, type of surgical resection, side effects after systemic treatment (deep vein thrombosis, hypertension, proteinuria), IDH1 and alpha thalassemia/mental retardation syndrome X-linked (ATRX) mutation status were investigated as prognostic factors for progression-free survival and overall survival.
Results
At the time of diagnosis, the median age was 48 (17–77) and 68% of the patients were male. Most common pathologic subtype was glioblastoma multiforme (68%). Median follow-up duration was 9.1 months (1–68 months). Median progression-free survival and overall survival were 6.2 months and 8 months, respectively. In multivariate analysis, ECOG PS, deep venous thrombosis and the presence of ATRX and IDH1 mutation were found to be independent prognostic factors for progression-free survival (p < 0.05) and, ECOG PS, the presence of ATRX and IDH1 mutation for overall survival (p < 0.05).
Conclusion
Our study is real life data and the median progression-free survival and overall survival rates are similar to the literature. We have found ECOG PS, presence of ATRX and IDH1 mutation to be independent prognostic factors for both progression-free survival and overall survival.
LouisDNOhgakiHWiestlerOD, et al. (eds). WHO classification of tumours of the central nervous system. 4th ed.Lyon:
IARC, 2016.
2.
OstromQTGittlemanHTruittG, et al.
CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015.Neuro Oncol2018;
20: iv1–iv86.
3.
LouisDNPerryAReifenbergerG, et al.
The 2016 World Health Organization classification of tumors of the central nervous system: a summary.Acta Neuropathol2016;
131: 803–820.
4.
van den BentMJWellerMWenPY, et al.
A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.Neuro Oncol2017;
19: 614–624.
5.
NickelKRenovanzMKönigJ, et al.
The patients’ view: impact of the extent of resection, intraoperative imaging, and awake surgery on health-related quality of life in high-grade glioma patients-results of a multicenter cross-sectional study. Neurosurg Rev2018;
41: 207–219.
6.
CorsoCDBindraRS ndMehtaMP.The role of radiation in treating glioblastoma: here to stay.J Neurooncol2017;
134: 479–485.
7.
StuppRMasonWPvan den BentMJ, et al.
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med2005;
352: 987–996.
8.
StuppRHegiMEMasonWP, et al.
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol2009;
10: 459–466.
9.
WellerMCloughesyTPerryJR, et al.
Standards of care for treatment of recurrent glioblastoma – are we there yet?Neuro Oncol2013;
15: 4–27.
10.
WillettCGBoucherYdi TomasoE, et al.
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med2004;
10: 145–147 (published correction appears in Nat Med 2004; 10: 649).
11.
TaalWOosterkampHMWalenkampAM, et al.
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol2014;
15: 943–953.
12.
FriedmanHSPradosMDWenPY, et al.
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.J Clin Oncol2009;
27: 4733–4740.
13.
ChinotOLWickWMasonW, et al.
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med2014;
370: 709–722.
14.
GilbertMRDignamJJArmstrongTS, et al.
A randomized trial of bevacizumab for newly diagnosed glioblastoma.N Engl J Med2014;
370(8):699–708. doi:10.1056/NEJMoa1308573
15.
Eckel-PassowJELachanceDHMolinaroAM, et al.
Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors.N Engl J Med2015;
372: 2499–2508.
16.
AgarwalSSharmaMCJhaP, et al.
Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.Neuro Oncol2013;
15: 718–726.
HeaphyCMde WildeRFJiaoY, et al.
Altered telomeres in tumors with ATRX and DAXX mutations.Science2011;
333: 425.
19.
KannanKInagakiASilberJ, et al.
Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.Oncotarget2012;
3: 1194–1203.
20.
IkemuraMShibaharaJMukasaA, et al.
Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas. Histopathology2016;
69: 260–267.
21.
ReniMMazzaEZanonS, et al.
Central nervous system gliomas.Crit Rev Oncol Hematol2017;
113: 213–234.
22.
ZhangGBCuiXLSuiDL, et al.
Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients. J Neurooncol2013;
113: 251–258.
23.
VredenburghJJDesjardinsAHerndonJE2nd, et al.
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.J Clin Oncol2007;
25: 4722–4729.
24.
SchaubCTichyJSchäferN, et al.
Prognostic factors in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol2016;
129: 93–100.
25.
StarkAMStepperW andMehdornHM.Outcome evaluation in glioblastoma patients using different ranking scores: KPS, GOS, mRS and MRC.Eur J Cancer Care (Engl)2010;
19: 39–44.
26.
KhojaLKumaranGZeeYK, et al.
Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer.J Clin Gastroenterol2014;
48: 430–434.
27.
LiauCTChouWCWeiKC, et al.
Female sex, good performance status, and bevacizumab-induced hypertension associated with survival benefit in Asian patients with recurrent glioblastoma treated with bevacizumab.Asia Pac J Clin Oncol2018;
14: e8–e14.
28.
SchneiderBPWangMRadovichM, et al.
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol2008;
26: 4672–4678 (published correction appears in J Clin Oncol 2009; 27: 3070].
29.
ZhongJAliANVoloschinAD, et al.
Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab. Cancer2015;
121: 1456–1462.
30.
HeitJASilversteinMDMohrDN, et al.
Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.Arch Intern Med2000;
160: 809–815.
31.
HorstedFWestJ andGraingeMJ.Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis.PLoS Med2012;
9: e1001275.
32.
RiedlJ andAyC.Venous thromboembolism in brain tumors: risk factors, molecular mechanisms, and clinical challenges.Semin Thromb Hemost2019;
45: 334–341.
33.
UnruhDSchwarzeSRKhouryL, et al.
Mutant IDH1 and thrombosis in gliomas.Acta Neuropathol2016;
132: 917–930.
34.
Mir Seyed NazariPRiedlJPreusserM, et al.
Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism.J Thromb Haemost2018;
16: 1121–1127.
35.
BozkayaYÖzdemirNErdemGU, et al.
Mortality risk analysis of asymptomatic and symptomatic venous thromboembolism in patients with metastatic colorectal cancer.J Cancer Res Ther2018;
14: 1330–1335.
36.
AlcalayAWunTKhatriV, et al.
Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival.J Clin Oncol2006;
24: 1112–1118.
37.
SimanekRVormittagRHasslerM, et al.
Venous thromboembolism and survival in patients with high-grade glioma.Neuro Oncol2007;
9: 89–95.
38.
SmithTRLallRRGrahamRB, et al.
Venous thromboembolism in high grade glioma among surgical patients: results from a single center over a 10 year period. J Neurooncol2014;
120: 347–352.
39.
SemradTJO’DonnellRWunT, et al.
Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg2007;
106: 601–608.
40.
SansonMMarieYParisS, et al.
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol2009;
27: 4150–4154.
41.
JuratliTAKirschMGeigerK, et al.
The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J Neurooncol2012;
110: 325–333 (published correction appears in J Neurooncol 2013; 111: 95. Schrok, E (corrected to Schrock, E)).
42.
MukasaATakayanagiSSaitoK, et al.
Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci2012;
103: 587–592.
43.
ChengHBYueWXieC, et al.
IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis. Tumour Biol2013;
34: 3555–3559.
44.
SchwartzentruberJKorshunovALiuXY, et al.
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature2012;
482: 226–231 (published correction appears in Nature 2012; 484: 130).
45.
CeramiEGaoJDogrusozU, et al.
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov2012;
2: 401–404 (published correction appears in Cancer Discov 2012; 2: 960).
46.
KoschmannCCalinescuAANunezFJ, et al.
ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.Sci Transl Med2016;
8: 328ra28.
47.
LiuJZhangXYanX, et al.
Significance of TERT and ATRX mutations in glioma.Oncol Lett2019;
17: 95–102.
48.
CaiHQWangPFZhangHP, et al.
Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1R132H mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss.J Clin Pathol2018;
71: 702–707.
49.
ChaurasiaAParkSHSeoJW, et al.
Immunohistochemical analysis of ATRX, IDH1 and p53 in glioblastoma and their correlations with patient survival.J Korean Med Sci2016;
31: 1208–1214.
50.
LeeperHECaronAADeckerPA, et al.
IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.Oncotarget2015;
6: 30295–30305.
51.
PekmezciMRiceTMolinaroAM, et al.
Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.Acta Neuropathol2017;
133: 1001–1016.
